FHIR R4 vs. R5: What Actually Changed and Does Your Healthcare Platform Need to Upgrade

If you are planning a patient-access API, payer–provider exchange, or a new clinical app on top of an EHR, someone on the call will ask: should we build on FHIR R4 or jump to R5? Influrion Solutions hears that question from CTOs and CIOs who already know FHIR is the right family of standards — they need a commercial answer about version risk, not a standards-committee tour.

Here is the short version: FHIR R4 remains the production default for most US and many global healthcare platforms in 2026. R5 is a real, published release with meaningful improvements — especially around subscriptions, obligations, and several clinical domains — but “newer” is not the same as “what your counterparties, certification programs, and Implementation Guides (IGs) actually speak.” Upgrade when a concrete capability or partner mandate requires R5; otherwise ship R4 with a clean versioning story.

What R4 and R5 actually are

FHIR R4 (Release 4) is the maturity milestone most product teams mean when they say “we support FHIR.” It is the baseline for a large share of regulatory and commercial profiles: US Core, many EHR SMART on FHIR apps, payer APIs, and bulk data pipelines. When vendors advertise “FHIR APIs,” they usually mean R4 resources over REST (JSON), often with OAuth2 / SMART scopes.

FHIR R5 (Release 5) is the next normative balloting release from HL7. It is not a tiny patch. It revises resource definitions, tightens some modeling, and adds or revises capabilities that product teams asked for after years of R4 production pain — notably around event-driven updates (subscriptions), clearer actor obligations, and updates across medication, imaging, and other domains.

Neither release replaces HL7 v2 on hospital floors. R4 and R5 are both resource-oriented, HTTP-native standards. The question is which resource version your platform should commit to for the next multi-year contract cycle.

R4 vs R5 at a glance

Dimension	FHIR R4	FHIR R5
Production footprint (2026)	Dominant for EHR apps, US Core–class profiles, many payer APIs	Growing; still fewer mandatory IGs and live counterparties
Typical buyer ask	“Are you FHIR R4 / US Core compatible?”	“Do you need R5-only features or an R5 partner?”
Subscriptions / push	Limited / IG-dependent patterns; often polling or custom webhooks	Substantially improved subscription model for event-driven apps
Modeling clarity	Mature but carries years of workarounds in some resources	Cleanups and revisions in several clinical domains
IG / certification risk	Lower — most certified paths still target R4	Higher until your IG and vendors catch up
Safe default for greenfield API	Yes, unless a requirement forces R5	Only when R5 is explicitly required or uniquely valuable

Use this table in architecture reviews. If the only argument for R5 is “it is newer,” stay on R4.

What actually changed in R5 (the buyer-relevant delta)

Standards changelogs are long. Platform owners care about a shorter list:

1. Better event-driven patterns (subscriptions)

R4 shops often reinvent “tell my app when Encounter status changes” with polling, HL7 v2 side channels, or vendor-specific webhooks. R5 invests more deliberately in subscription semantics so apps can register interest and receive timely updates. If your product is a real-time care-coordination cockpit or a task inbox that cannot tolerate stale lists, this is the strongest product reason to evaluate R5 — after you confirm the EHR or intermediary you depend on exposes it.

2. Clearer obligations and actor expectations

Interoperability fails when “support FHIR” means different things to a payer, a provider, and a SaaS vendor. R5 continues the push toward clearer obligation language so Implementation Guides can say who must send, who must receive, and what “support” means. For CTOs, that reduces ambiguous RFPs later — but only once your chosen IGs adopt those patterns.

3. Clinical domain revisions (medication, imaging, and friends)

R5 revises several high-traffic clinical areas. Medication workflows, imaging-related resources, and other domains pick up modeling lessons from R4 deployments. If your roadmap is deep in one of those domains and your partner ecosystem is moving, read the resource-level diffs before you freeze an internal canonical model. If your API surface is mostly Patient, Encounter, Observation, Condition, and DocumentReference for patient access, R4 remains ample.

4. Not a free rename

Resource names often look familiar; field paths, cardinality, and CodeSystem bindings do not always. Treat R5 as a breaking platform upgrade, not a config flag. Mapping layers, FHIRPath expressions, validation packages, and stored FHIR JSON all need a migration plan.

Why most platforms should still ship R4 first

Counterparties speak R4

Your platform does not choose a FHIR version in a vacuum. EHRs, HIEs, clearinghouses, and payer gateways expose the version their certified stacks and customer contracts require. In 2026 that is still overwhelmingly R4 for US patient-access and many provider-facing SMART apps.

Implementation Guides lag the base standard

US Core and peer national IGs are what auditors and integration partners actually test against. Until the IG you must claim (or the IG your biggest customer demands) is R5-native, an R5-only server is a lonely island. Many teams run R4 externally and keep internal models version-agnostic.

Talent, tooling, and validators

Most FHIR libraries, synthetic patient generators, and vendor sandboxes are battle-tested on R4. Your engineers will find more Stack Overflow answers, more sample Bundles, and more peer review for R4 profiles. That is not stagnation — it is operational maturity.

Regulatory and commercial checklists still say R4

When an RFP or ONC-era checklist says “FHIR,” decode which release and IG they mean. Assuming R5 earns bonus points is a common mistake; assuming R4 is “legacy” is the opposite mistake. Ask for the exact package IDs (for example, US Core version) in writing.

When an R5 upgrade is justified

Upgrade — or dual-support R5 — when at least one of these is true:

1. A must-win counterparty only exposes or requires R5 for a workflow you cannot replace (rare but decisive).
2. You need R5 subscription semantics (or another R5-only capability) and the upstream system actually implements it — not just the base spec PDF.
3. Your product is the FHIR server of record for a greenfield network that can mandate R5 end-to-end (closed ecosystem: your apps + your partners + your IG).
4. You are rewriting the integration layer anyway (major EHR swap, multi-year platform rebuild) and R5 aligns with the 3–5 year IG roadmap you have confirmed with customers.

Do not upgrade because:

• Marketing wants “R5-ready” on a slide without a customer who asked.
• A single microservice team prefers newer resource shapes while the rest of the estate is R4.
• You hope R5 will fix messy master patient index / identity problems (it will not; identity hygiene is orthogonal).

A practical decision checklist for CTOs / CIOs

Run this workshop before you change the platform default:

#	Question	If “no” / unclear
1	Which FHIR release + IG packages do our top 3 counterparties certify today?	Default to their intersection (almost always R4-class).
2	Which of our user journeys need push/subscriptions vs nightly sync / on-demand GET?	Prefer R4 + proven sync unless R5 subscriptions are available upstream.
3	Do we store raw FHIR JSON long-term, or map into an internal canonical model?	Raw JSON lock-in raises upgrade cost — invest in mapping.
4	Can we dual-run R4 and R5 façades for 12–24 months?	If not, do not flip the public version until partners are ready.
5	Who owns validation packages, terminology, and breaking-change regression tests?	No owner → no upgrade.
6	What is the rollback plan if a partner’s R5 endpoint is incomplete?	Feature-flag the façade; keep R4 path hot.

Print the table. Fill it in a single architecture review. Influrion’s bias from delivery work: R4 externally until the checklist forces otherwise; design internals so a second façade is possible.

Architecture pattern that ages well

Regardless of release choice, structure the platform like this:

1. Internal canonical model (your domain objects) — not “whatever the last Bundle looked like.”
2. FHIR façade(s) — R4 now; optional R5 later — with explicit version in CapabilityStatement and URLs.
3. Mapping + terminology services — CodeSystems, ConceptMaps, and identifier strategy owned by a platform team.
4. Contract tests against the IGs you claim — not against a happy-path Postman collection alone.
5. Observability — correlate FHIR OperationOutcome, HTTP status, and patient/encounter identifiers for support.

This pattern is how you avoid a two-year hostage situation when R6 (or the next mandatory IG) arrives. Version upgrades become façade work, not a rewrite of clinical workflows.

Migration pitfalls we see repeatedly

• Assuming resource parity. A field that “looked the same” in R4 samples may be renamed, moved, or constrained differently in R5.
• Ignoring search parameter differences. Apps break on _include, chaining, and custom search params long before UI looks wrong.
• Skipping CapabilityStatement honesty. Advertising R5 while only implementing a subset burns trust in the first pilot.
• Forgetting SMART / scopes. Authorization scopes and launch contexts are part of the product contract; re-test with real EHR sandboxes.
• Big-bang cutover. Dual-running façades with traffic shaping beats a weekend flip for multi-tenant SaaS.

FAQ

Is FHIR R4 obsolete now that R5 exists?

No. R4 remains the production workhorse for a large share of healthcare APIs and Implementation Guides. Obsolescence would show up as counterparties and mandatory IGs leaving R4 — that has not become the default story for most platforms in 2026.

Can we support R4 and R5 at the same time?

Yes, and that is often the right enterprise answer. Expose versioned endpoints or separate base URLs, keep mapping in one place, and let each partner attach to the release their stack supports. Dual support costs engineering time; big-bang upgrades cost incidents.

Will choosing R5 make us more “future-proof”?

Only if your customers and regulators are moving with you. Future-proofing comes from clean façades, IG-driven contract tests, and terminology discipline — not from picking the newest base release early.

What should we put in an RFP response today?

State the exact FHIR release and IG packages you implement (for example, FHIR R4 plus the US Core version you validate). If you have an R5 roadmap, date it and name the features (subscriptions, specific resources) rather than a vague “R5-ready” claim.

Does Influrion Solutions build R4 or R5 integrations?

Influrion Solutions is a software and healthcare IT company that designs FHIR-facing platforms around what your counterparties and compliance programs actually require — typically R4 today, with R5 when the checklist justifies it. We map HL7 v2, FHIR, and imaging workflows into maintainable façades rather than locking you to one vendor’s sample Bundle.

Closing

FHIR R5 is a meaningful standards step, not a mandatory platform reboot. For most healthcare products, R4 is still the rational external contract in 2026; R5 becomes compelling when subscriptions, domain revisions, or a concrete partner mandate create measurable value that outweighs migration risk.

If you are freezing a FHIR version for a multi-year platform bet — or you need a dual R4/R5 façade plan — contact Influrion Solutions with the counterparties and IGs on your critical path. We will help you pick the release that matches reality, not the release that looks newest on a slide.